Table 4: GvHD and outcome in patients according to ATG administration.

Characteristic (% of patients) ATG +;
n = 11
Non-ATG
n = 11
P
aGvHD 55% 64% 0.5
aGvHD 1-2 grade 27% 27% -
aGvHD 3-4 grade 27% 36% 0.7
cGvHD 60% 100% 0.0001a
Extended cGvHD
Relapse after alloSCT
22%
27%
50%
45%
0.05a
0.1
Overall mortality 54% 45% -
TRM 27% 27% -

GvHD: Graft-Versus-Host Disease; ATG: Anti-Thymocyte Globulin; aGvHD: Acute Gvhd; cGvHD: Chronic GvHD; alloSCT: Allogeneic Stem Cell Transplantation; TRM: Treatment Related Mortality; aSignificant, P value < 0.05.